Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hormonal Regulation01:40

Hormonal Regulation

Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
Regulation of Hormone Secretion01:19

Regulation of Hormone Secretion

Regulation of hormone secretion is a finely tuned orchestration driven by various types of stimuli, encompassing neural, humoral, and hormonal signals. Environmental cues instigate neural stimuli, where action potentials traverse nerve fibers to reach their designated targets. An illustrative scenario is the body's response to stress, wherein the sympathetic nervous system releases epinephrine from the adrenal glands, inducing the well-known 'fight or flight' reaction.
Humoral stimuli,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Managing PMS and perimenopause symptoms. The role of compounded medications.

Advance for nurse practitioners·2003
See all related articles

Related Experiment Video

Updated: May 8, 2026

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Hormone Therapy: It's Time for a Second Opinion.

Joseph J Collins1, Marla Ahlgrimm

  • 1Women's Health America, Madison, Wisconsin.

International Journal of Pharmaceutical Compounding
|August 24, 2013
PubMed
Summary
This summary is machine-generated.

This opinion paper questions the safety and efficacy of compounded bioidentical hormones, but overlooks existing research and regulatory support for individualized hormone replacement therapy. Clinicians should consider all evidence when making patient care decisions.

More Related Videos

An Ex vivo Model to Study Hormone Action in the Human Breast
12:31

An Ex vivo Model to Study Hormone Action in the Human Breast

Published on: January 8, 2015

Related Experiment Videos

Last Updated: May 8, 2026

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

An Ex vivo Model to Study Hormone Action in the Human Breast
12:31

An Ex vivo Model to Study Hormone Action in the Human Breast

Published on: January 8, 2015

Area of Science:

  • Endocrinology
  • Pharmacology
  • Women's Health

Background:

  • An opinion paper on compounded bioidentical hormones was published by the American College of Obstetricians and Gynecologists in 2005.
  • This paper has the potential to influence clinical practice regarding hormone therapy.
  • Concerns exist regarding the paper's accurate representation of scientific literature and regulatory landscape.

Purpose of the Study:

  • To critically evaluate the 2005 ACOG opinion paper on compounded bioidentical hormones.
  • To highlight potential inaccuracies and omissions in the paper's assessment of bioidentical hormone therapy.
  • To provide a balanced perspective on the use of compounded hormone preparations.

Main Methods:

  • Literature review and critical analysis of the ACOG opinion paper.
  • Examination of referenced studies for accurate reporting on safety and efficacy.
  • Assessment of regulatory status and legal precedents for compounded prescriptions.
  • Comparison of stated opinions with scientific literature on hormone level correlations.

Main Results:

  • The ACOG paper may misrepresent findings on bioidentical hormone safety and efficacy.
  • It fails to acknowledge mass-produced bioidentical hormone preparations and FDA-approved flexible dosing.
  • The paper overlooks legal and regulatory support for compounded hormone replacement therapy.
  • Correlations between plasma and salivary hormone levels are not addressed.

Conclusions:

  • The ACOG opinion paper's stance against compounded bioidentical hormones is not fully supported by evidence or regulatory context.
  • Clinicians should critically assess such opinions and consider a broader range of scientific and legal information.
  • Individualized dosing for hormone therapy remains a relevant consideration.